window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Artificial Intelligence

  • Artificial Intelligence,Drug discovery,Research & Development,Technology and platforms

    Chemify founder publishes three papers on programmable chemistry and automated drug discovery

    Chemify founder Lee Cronin has published three peer-reviewed papers outlining [...]

    April 10, 2026
  • Artificial Intelligence,Biotech,Drug Development,Drug discovery,Research & Development

    ProQR partners with Ginkgo Bioworks for AI-driven RNA editing development and forms advisory board

    ProQR Therapeutics has entered a collaboration with Ginkgo Bioworks to [...]

    April 9, 2026
  • Artificial Intelligence,Drug discovery,Funding,Technology and platforms

    DeepCyte raises $1.5M to advance single-cell AI toxicology platform for drug development

    DeepCyte, a techbio company developing AI-driven toxicology tools for drug [...]

    April 9, 2026
  • Artificial Intelligence,Drug Development,Drug discovery,Research & Development,Technology and platforms

    William Blair highlights Carterra as key player in AI-driven drug discovery shift

    A new analyst report from William Blair has highlighted Carterra [...]

    April 9, 2026
  • Artificial Intelligence,Clinical Development,Genomics and sequencing,Obesity,Precision medicine,Technology and platforms

    23andMe study links genetics to GLP-1 weight loss outcomes and side effects

    This Nature-published study from the 23andMe Research Institute identifies genetic [...]

    April 9, 2026
  • Artificial Intelligence,Clinical studies,Drug discovery,Neurosciences,Pharmaceuticals and therapeutics

    AI-derived drug candidate reduces fentanyl intake in preclinical opioid study

    A study published in Proceedings of the National Academy of [...]

    April 8, 2026
  • Artificial Intelligence,Biotech,Research & Development,Technology and platforms

    Nanotube injector enables controlled cytoplasmic transfer between living cells

    Researchers in Japan have developed a nanotube-based system that enables [...]

    April 7, 2026
  • Artificial Intelligence,Diagnostics,Digital Health,Medical devices,Women's Health

    Diagnoly launches Fetoly on iOS for real-time fetal ultrasound AI

    Diagnoly has launched its fetal ultrasound AI tool Fetoly on [...]

    April 7, 2026
  • Artificial Intelligence,Drug discovery,Partnerships & Funding

    Insilico Medicine signs $2.75bn AI drug discovery deal with Eli Lilly

    Insilico Medicine has signed a drug discovery collaboration with Eli [...]

    March 31, 2026
  • Artificial Intelligence,Digital Health,Mental health,Neurosciences,Research & Development

    Bullfrog AI signs commercial agreement with top 5 global pharma company to identify novel target in major depressive disorder

    BullFrog AI Holdings has entered a commercial agreement with a [...]

    March 30, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top